These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2128509)

  • 1. Does FAD-dependent polyamine oxidase contribute to the metabolism of milacemide?
    Strolin Benedetti M; Cocchiara G; Colombo M; Dostert P
    J Neural Transm Suppl; 1990; 32():351-6. PubMed ID: 2128509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of FAD-dependent polyamine oxidase in the metabolism of milacemide in the rat.
    Strolin Benedetti M; Allievi C; Cocchiara G; Pevarello P; Dostert P
    Xenobiotica; 1992 Feb; 22(2):191-7. PubMed ID: 1632108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B.
    Janssens de Varebeke P; Cavalier R; David-Remacle M; Youdim MB
    J Neurochem; 1988 Apr; 50(4):1011-6. PubMed ID: 3346666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAO activity, metabolism and anticonvulsant activity of milacemide in rats and mice.
    Colombo M; Strolin Benedetti M; Bonsignori A; Cocchiara G; Roncucci R; Dostert P
    J Neural Transm Suppl; 1990; 32():123-9. PubMed ID: 2089081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?
    O'Brien EM; Tipton KF; Strolin Benedetti M; Bonsignori A; Marrari P; Dostert P
    Biochem Pharmacol; 1991 Jun; 41(11):1731-7. PubMed ID: 2043162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.
    Semba J; Curzon G; Patsalos PN
    Br J Pharmacol; 1993 Apr; 108(4):1117-24. PubMed ID: 8485621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interactions of milacemide with monoamine oxidase.
    O'Brien EM; Tipton KF; McCrodden JM; Youdim MB
    Biochem Pharmacol; 1994 Feb; 47(4):617-23. PubMed ID: 8129740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase.
    O'Brien EM; Dostert P; Pevarello P; Tipton KF
    Biochem Pharmacol; 1994 Aug; 48(5):905-14. PubMed ID: 8093103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Milacemide, a glycine pro-drug, inhibits strychnine-allodynia without affecting normal nociception in the rat.
    Khandwala H; Loomis CW
    Pain; 1998 Jul; 77(1):87-95. PubMed ID: 9755023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B.
    Janssens de Varebeke P; Pauwels G; Buyse C; David-Remacle M; De Mey J; Roba J; Youdim MB
    J Neurochem; 1989 Oct; 53(4):1109-16. PubMed ID: 2769256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase inhibitory properties of milacemide in rats.
    Truong DD; Diamond B; Pezzoli G; Mena MA; Fahn S
    Life Sci; 1989; 44(15):1059-66. PubMed ID: 2784529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitors.
    Krysiak JM; Kreuzer J; Macheroux P; Hermetter A; Sieber SA; Breinbauer R
    Angew Chem Int Ed Engl; 2012 Jul; 51(28):7035-40. PubMed ID: 22689512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the glycine prodrug milacemide (2-N-pentylaminoacetamide) on catecholamine secretion from isolated adrenal medulla chromaffin cells.
    Yadid G; Zinder O; Youdim MB
    Br J Pharmacol; 1991 Nov; 104(3):760-4. PubMed ID: 1797336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular pharmacology of L-deprenyl.
    Gerlach M; Riederer P; Youdim MB
    Eur J Pharmacol; 1992 Jun; 226(2):97-108. PubMed ID: 1639115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of vocal and nonvocal behavior in adult squirrel monkeys by selective MAO-A and MAO-B inhibition.
    Newman JD; Winslow JT; Murphy DL
    Brain Res; 1991 Jan; 538(1):24-8. PubMed ID: 1902133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of amine oxidases in xenobiotic metabolism.
    Gong B; Boor PJ
    Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):559-71. PubMed ID: 16859404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microionophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells.
    Godfraind JM
    Br J Pharmacol; 1990 May; 100(1):119-25. PubMed ID: 2196964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detoxification of the polyamine analogue N1-ethyl-N11-[(cycloheptyl)methy]-4,8-diazaundecane (CHENSpm) by polyamine oxidase.
    Lawson KR; Marek S; Linehan JA; Woster PM; Casero RA; Payne CM; Gerner EW
    Clin Cancer Res; 2002 May; 8(5):1241-7. PubMed ID: 12006544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 30-angstrom-long U-shaped catalytic tunnel in the crystal structure of polyamine oxidase.
    Binda C; Coda A; Angelini R; Federico R; Ascenzi P; Mattevi A
    Structure; 1999 Mar; 7(3):265-76. PubMed ID: 10368296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.